Professor Chris Goldring is Vice President for Academic Affairs at Xi’an Jiaotong-Liverpool University (XJTLU), bringing extensive experience in academic leadership and international collaboration. Prior to joining XJTLU in this role, he served as Deputy Executive Dean of the Institute for Systems, Molecular and Integrative Biology; Deputy Head of Department, and Pharmacology BSc Programme Lead at the University of Liverpool.
Throughout his career, Professor Goldring has contributed to academic strategy, programme development, and departmental management. At XJTLU, he draws on his experience in UK higher education to support the University’s academic strategy, enhance teaching and learning, promote programme innovation, and foster an international academic community.
Professor Goldring is a pharmacologist whose research focuses on improving drug safety through more human-relevant experimental models and biomarkers. His work aims to better predict adverse drug reactions and support safer medicine development and use. He has led major national and international initiatives to advance 3D cell culture, systems toxicology, and liver research, helping develop widely adopted industry roadmaps for drug safety assessment.
Professor Goldring has played an important role in strengthening collaboration between the University of Liverpool and XJTLU. As Co-Director of the XJTLU-University of Liverpool Joint Centre for Pharmacology and Therapeutics, he helped advance joint education, training, and research. He has also led national and international initiatives and collaborated with industry, professional organisations, and regulatory bodies to translate academic expertise into practical impact.
A Fellow of the British Pharmacological Society, Professor Goldring has served on various professional and regulatory committees, including grant funding panels and expert advisory bodies of the Medicines and Healthcare products Regulatory Agency (MHRA). He is a recipient of a Queen’s Award medal for his contributions to safe and effective medicines, reflecting his commitment to academic excellence and the practical application of research.
